J. Santoro

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients

Ira M. Jacobson, Robert S. Brown, Bradley Freilich et al. · Hepatology · 2007 · 306 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

The validity and accuracy of the Work Productivity and Activity Impairment questionnaire – irritable bowel syndrome version (WPAI:IBS)

Margaret C. Reilly, A. Bracco, J.F. Ricci et al. · Alimentary Pharmacology & Therapeutics · 2004 · 198 citations

Medicine, Clinical Sciences, Internal Medicine +17

736 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trial

Doug Dieterich, E. Läwitz, Ziad Younes et al. · Journal of Hepatology · 2006 · 46 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Antiviral Response of HCV Genotype 1 to Consensus Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin

Maria H. Sjögren, Robert W. Sjogren, M.F. Lyons et al. · Digestive Diseases and Sciences · 2007 · 37 citations

Life Sciences, Immunology, Infectious Diseases +17